 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inhibikase Therapeutics: Q3 Earnings Insights

Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ETBOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or...

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter...

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ( Inhibikase or Company ), a clinical-stage pharmaceutical company developing protein kinase...

Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023

BOSTON and ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase...

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase...

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase...

Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib PR Newswire BOSTON and ATLANTA...

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders PR Newswire BOSTON and ATLANTA, Aug. 22, 2023 BOSTON and ATLANTA, Aug. 22...

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib PR Newswire BOSTON and ATLANTA, Aug. 21, 2023 - Company...

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

Watchers	1,777
52-Wk Low	$0.79
52-Wk High	$6.94

Market Cap	$5.66M
Volume (M)	30,115.00
52-Wk High	$6.94
52-Wk Low	$0.79

IKT Inhibikase Therapeutics Inc

About

Feed

News

Earnings

Fundamentals